Press Releases

Date Title
2/22/22 Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Developments on March 1, 2022
2/1/22 Sarepta Therapeutics and GenEdit Share Progress on Research Collaboration and Announce Agreement to Develop Gene Editing Therapeutics for Neuromuscular Diseases
1/31/22 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/10/22 Sarepta Therapeutics’ Gene Therapy SRP-9001 Shows Statistically Significant Functional Improvements Compared to Pre-specified Matched External Control in Part 2 of Study SRP-9001-102 for the Treatment of Duchenne Muscular Dystrophy
1/6/22 Sarepta Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
12/31/21 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/30/21 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/17/21 Sarepta Therapeutics Names Louise Rodino-Klapac, Ph.D., Head of Research and Development
11/17/21 Sarepta Therapeutics Appoints Stephen L. Mayo, Ph.D., to its Board of Directors
11/3/21 Sarepta Therapeutics Announces Third Quarter 2021 Financial Results and Recent Corporate Developments
Displaying 101 - 110 of 812